Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…
![Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement](https://i1.wp.com/ml-eu.globenewswire.com/media/MjU1NjVjOWEtMTBjOC00MTE0LWI0NTUtYjdlMjkzODM0MzYzLTEyMjA5NDY=/tiny/Zelluna-ASA.png?w=420&resize=420,280&ssl=1 "Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement")
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement
March 03, 2025 10:46 ET | Source: Zelluna ASA Oslo, Norway, 03…
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Poolbeg Pharma plc (Poolbeg or the Company) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN,…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE…
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival…
TECVAYLI (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD…
Five-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a…